MicroPort Endovascular MedTech Ltd (688016) - Total Liabilities
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has total liabilities worth CN¥554.42 Million CNY (≈ $81.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore MicroPort Endovascular MedTech Ltd equity growth rate to track the company's year-over-year net asset growth rate.
MicroPort Endovascular MedTech Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of MicroPort Endovascular MedTech Ltd to measure how efficiently the company converts operating cash flow to free cash.
MicroPort Endovascular MedTech Ltd Competitors by Total Liabilities
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PLUXEE NV
PA:PLX
|
France | €5.93 Billion |
|
Sanquan Food Co Ltd
SHE:002216
|
China | CN¥3.04 Billion |
|
Nuvoton Technology Corp
TW:4919
|
Taiwan | NT$17.35 Billion |
|
Peker Gayrimenkul Yatirim Ortakligi AS
IS:PEKGY
|
Turkey | TL3.30 Billion |
|
Devyani International Limited
NSE:DEVYANI
|
India | Rs42.48 Billion |
|
Killam Apartment Real Estate Investment Trust
TO:KMP-UN
|
Canada | CA$2.48 Billion |
|
Fujian Kuncai Material Tech
SHG:603826
|
China | CN¥3.01 Billion |
|
Mister Car Wash, Inc. Common Stock
NYSE:MCW
|
USA | $2.04 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down MicroPort Endovascular MedTech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of MicroPort Endovascular MedTech Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MicroPort Endovascular MedTech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual total liabilities of MicroPort Endovascular MedTech Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-3.98 Billion ≈ $-582.73 Million |
-948.88% |
| 2024-12-31 | CN¥469.13 Million ≈ $68.65 Million |
+22.60% |
| 2023-12-31 | CN¥382.63 Million ≈ $55.99 Million |
+51.54% |
| 2022-12-31 | CN¥252.49 Million ≈ $36.95 Million |
+9.08% |
| 2021-12-31 | CN¥231.47 Million ≈ $33.87 Million |
+62.90% |
| 2020-12-31 | CN¥142.09 Million ≈ $20.79 Million |
+58.34% |
| 2019-12-31 | CN¥89.74 Million ≈ $13.13 Million |
+70.41% |
| 2018-12-31 | CN¥52.66 Million ≈ $7.71 Million |
+45.29% |
| 2017-12-31 | CN¥36.24 Million ≈ $5.30 Million |
-44.43% |
| 2016-12-31 | CN¥65.22 Million ≈ $9.54 Million |
-- |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more